Retatrutide: The Triple Agonist Changing Weight Loss Research
Retatrutide simultaneously targets GIP, GLP-1, and glucagon receptors, making it the most potent metabolic peptide studied to date. Here's what the clinical data shows.
Retatrutide (LY3437943) is a once-weekly injectable peptide developed by Eli Lilly that acts as a triple agonist at GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. This multi-receptor approach distinguishes it from existing GLP-1 mono-agonists and dual GLP-1/GIP agonists.
Triple Receptor Mechanism
GLP-1 Agonism
Slows gastric emptying, reduces appetite, and improves insulin secretion. This is the same pathway targeted by semaglutide and tirzepatide.
GIP Agonism
GIP enhances insulin secretion in a glucose-dependent manner and may reduce nausea associated with GLP-1 agonism. In adipose tissue, GIP promotes fat storage when energy is available and release during deficit.
Glucagon Agonism
Glucagon traditionally raises blood glucose but also drives energy expenditure and fat oxidation in the liver. Retatrutide's glucagon component is thought to accelerate fat burning without substantially raising fasting glucose due to concurrent GLP-1 and GIP activity counterbalancing glycemic effects.
Phase 2 Clinical Results
The Phase 2 TRIUMPH trial (published in The New England Journal of Medicine, 2023) produced remarkable results:
- ·Up to 24.2% reduction in body weight at 48 weeks (highest dose cohort)
- ·Dose-dependent response observed across all cohorts
- ·Significant improvements in waist circumference, blood pressure, and lipid profiles
- ·Also studied in type 2 diabetes populations with meaningful HbA1c reduction
These figures surpass previously published data for semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in comparable timeframes.
Research Considerations
Retatrutide is still in clinical trials as of 2025. Phase 3 trials (TRIUMPH-3 and others) are ongoing. It is not yet approved for any medical use.
As a research peptide, retatrutide allows investigators to study:
- ·Tri-receptor agonism pharmacology
- ·Metabolic flexibility and energy expenditure
- ·Mechanisms of GLP-1-driven appetite suppression
- ·Comparative efficacy vs. mono- and dual-agonist approaches
Storage
Retatrutide peptide is sensitive to temperature. Store lyophilized powder as directed and protect from repeated freeze-thaw cycles.
Note: Retatrutide is sold strictly for research purposes. Not for human use.